Skip navigation
Skip navigation

Recombinant human thyrotropin in the management of thyroid disorders

Da Paz Filho, Gilberto; Graf, Hans

Description

Background: Recombinant human thyroid stimulating hormone (rhTSH) is a valuable tool in the management of thyroid diseases. It is useful for radioiodine ablation in patients with differentiated thyroid carcinoma (DTC), for their follow-up, and for treatment of selected patients with metastatic or recurrent DTC. More recently, it has been suggested that rhTSH is useful for treatment of multinodular goiter and amiodarone-induced thyrotoxicosis, as well as for diagnosis of congenital...[Show more]

dc.contributor.authorDa Paz Filho, Gilberto
dc.contributor.authorGraf, Hans
dc.date.accessioned2015-12-08T22:16:46Z
dc.identifier.issn1471-2598
dc.identifier.urihttp://hdl.handle.net/1885/30826
dc.description.abstractBackground: Recombinant human thyroid stimulating hormone (rhTSH) is a valuable tool in the management of thyroid diseases. It is useful for radioiodine ablation in patients with differentiated thyroid carcinoma (DTC), for their follow-up, and for treatment of selected patients with metastatic or recurrent DTC. More recently, it has been suggested that rhTSH is useful for treatment of multinodular goiter and amiodarone-induced thyrotoxicosis, as well as for diagnosis of congenital hypothyroidism. Objective: To provide an outline of literature regarding the uses of rhTSH in thyroid diseases. Methods: We performed a literature search for relevant articles in the PubMed database. Conclusion: rhTSH has important roles in management of thyroid diseases, and some are still controversial. For patients with DTC, it avoids the need for thyroid hormone withdrawal, without being detrimental to short-term outcomes. Further studies are warranted to assess its effects on long-term outcomes.
dc.publisherAshgate Publishing Ltd
dc.sourceExpert Opinion on Biological Therapy
dc.subjectKeywords: corticosteroid; glucocorticoid; iodine 131; levothyroxine; placebo; radioactive iodine; recombinant thyrotropin; thyroglobulin; thyroglobulin antibody; thyroid hormone; thyrotropin; adjuvant therapy; asthenia; clinical trial; congenital hypothyroidism; di Goiter; Radioiodine; Recombinant TSH; Thyroid cancer; Thyrotropin
dc.titleRecombinant human thyrotropin in the management of thyroid disorders
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume8
dc.date.issued2008
local.identifier.absfor110306 - Endocrinology
local.identifier.ariespublicationu4693331xPUB77
local.type.statusPublished Version
local.contributor.affiliationDa Paz Filho, Gilberto, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationGraf, Hans, Federal University of Parana
local.description.embargo2037-12-31
local.bibliographicCitation.issue11
local.bibliographicCitation.startpage1721
local.bibliographicCitation.lastpage32
local.identifier.doi10.1517/14712598.8.11.1721
local.identifier.absseo970111 - Expanding Knowledge in the Medical and Health Sciences
dc.date.updated2016-02-24T11:18:11Z
local.identifier.scopusID2-s2.0-56249146704
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Da Paz Filho_Recombinant_human_thyrotropin_2008.pdf15.36 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator